Publication: Anti-thrombotic and Anticoagulant Treatment in Interventional Cardiology
Issued Date
1998-01-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-2442676785
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.81, No.1 (1998), 41-46
Suggested Citation
Nithi Mahanonda Anti-thrombotic and Anticoagulant Treatment in Interventional Cardiology. Journal of the Medical Association of Thailand. Vol.81, No.1 (1998), 41-46. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18591
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Anti-thrombotic and Anticoagulant Treatment in Interventional Cardiology
Author(s)
Other Contributor(s)
Abstract
Efforts to improve Percutaneous Transluminal Coronary Angioplasty (PTCA) have resulted in the usage of new antiplatelets, and antithrombotic agents. These new agents may increase bleeding complications. However, EPIC, EPILOG and CAPTURE trials showed benefits of 7E3, a GPIIb/IIIa platelets receptor blocker, in high risk PTCA patients. On the other hand, direct thrombin inhibitors, Hirudin and Hirulog, did not clearly show any benefit when compared to heparin in patients with unstable angina undergoing PTCA. Combination of oral antiplatelets, ticlopidine and aspirin, is widely utilized following stent implantation. However, its benefit over aspirin alone has not been demonstrated. This article aims to review mechanisms and benefits of these new agents in cardiovascular field.